European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, Frankfurt a. Main, Germany

Watch

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Dossier

The dossier is a printable PDF file, summarizing information and publications for this company. The creation of dossiers is included in your subscription. After the creation of the dossier is completed, it will be sent to your email address .

Add to dossier (if available):

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Name

Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Stiftung

Identification

Lei
529900YV08XPDWAY8008

Address

Paul-Ehrlich-Str. 42-44, 60596 Frankfurt a. Main, Germany

Financials

History

CSV export

Investigative Journalism

Uncover International Corporate Connections with our Free Investigative-Account

Publications

16 Oct 2023
Patent: Methods for Identifying and Stratifying Cancers and Cancer Patients Based on P2X4 Receptor Expression
7 Sept 2023
Patent: Urolithins and T-Cell Mediated Immune Response
7 Sept 2022
Patent: Urolithins and T-Cell Mediated Immune Response
1 Sept 2022 in Fk
Public funding (€765,704): SATURN3 network - Spatial and temporal resolution of intratumoral heterogeneity in the three difficult-to-treat cancers breast cancer, colorectal cancer and pancreatic …
18 Mar 2022
Patent: Therapeutic Combinations Including Inhibitors of the P2X4 Receptor for Treating and Preventing Proliferative Disorders
3 Mar 2022
Patent: Bispecific Antibodies Enhancing Cell Mediated Immune Responses
13 Dec 2021 as CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS STIFTUNG
EU funding (€2,500,000): Cell Plasticity in Metastatic Colorectal Cancer
13 Oct 2021
Patent: Fibronectin or ILK Inhibitors for USE in the Treatment of Leukemia
15 Sept 2021
Patent: Means for Reducing Radio- and Chemotherapy Resistance and Adverse Effects
18 Mar 2021
Patent: Therapeutic Combinations Including Inhibitors of the P2X4 Receptor for Treating and Preventing Proliferative Disorders
16 Sept 2020
Patent: Means for Reducing Radiotherapy Resistance and Adverse Effects
21 Aug 2020 in Hor
EU funding (€252,788): Exploring cell-to-cell heterogeneity and exploiting epigenetic regulation for the interception of myeloid disease cells.
26 May 2020
Patent: Therapeutic Combinations Comprising Agonists of Ferroptosis for Treating Proliferative Disorders
6 May 2020
Patent: CAR-Expressing NK-92 Cells AS Cell Therapeutic Agents
1 May 2020 in Hor
EU funding (€737,754): EUbOPEN: Enabling and Unlocking biology in the OPEN
28 Aug 2019
Patent: Chimeric Antigen Receptors with an Optimized Hinge Region
24 Jul 2019
Patent: Interleukin 15 AS Selectable Marker for Gene Transfer in Lymphocytes
18 Oct 2018
Patent: Methods and Compounds for Improved Immune Cell Therapy
19 Jul 2018
Patent: Periostin Compounds for the Treatment of Haematological Complications
15 Nov 2017
Patent: Chimeric Antigen Receptors with an Optimized Hinge Region
8 Sept 2016
Patent: Fibronectin for USE in the Treatment of Leukemia
17 Aug 2016
Patent: Chimeric Antigen Receptors with an Optimized Hinge Region
18 Mar 2016
Patent: HER2/Erbb2 Chimeric Antigen Receptor
13 Jul 2015 as CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS STIFTUNG
EU funding (€1,500,000): Functional and Molecular Analyses of the Interplay between Hematopoietic and Mesenchymal Niche Cells in Human Myelodysplastic Syndromes.
1 Apr 2015 in Fk
Public funding (€154,850): Network Auto-inflammatory syndromes in children and adolescents (AID-Net), subproject 3, Frankfurt
1 Sept 2014 in Fk
Public funding (€76,348): Network Auto-inflammatory syndromes in children and adolescents (AID-NET), subproject 3: Analysis of NF-kappaB-mediated regulatory mechanisms of interleukin-1 beta secretion
1 Feb 2014 in Fk
Public funding (€140,500): HIVERA VIHDUAVAX: Development of a new HIV-1 vaccine with bivalent properties by combining two gp41 epitopes: neutralization of HIV-1 and CD4 cell depletion
1 Dec 2012 in Fts
EU funding: Gene Therapy for X-Linked Chronic Granulomatous Disease (CGD)
1 Dec 2012 in Fts
EU funding: Gene Therapy for X-Linked Chronic Granulomatous Disease (CGD)
1 Dec 2012 in Fts
EU funding: Gene Therapy for X-Linked Chronic Granulomatous Disease (CGD)
1 Oct 2012 in Fk
Public funding (€488,443): CI3: Targeted killer cells for cancer immunotherapy, project part Georg-Speyer-Haus
10 Mar 2011
Patent: Stat3 Activation Inhibitors
1 Nov 2010 in Fts
EU funding (€514,900): Cell-PID
1 May 2010 in Fk
Public funding (€322,296): E-RARE-Verbund: Genetics and pathogenesis of septic granulomatosis and development of new gene therapy approaches (EURO-CGD ) subproject Frankfurt.
10 Mar 2010 as Georg-Speyer-Haus Chemotherapeutisches Forschungsinstitut
Patent: Targeted Protein Degradation Vehicles (TPDVs), Nucleic Acid Constructs Encoding Them and Their USE
1 Feb 2009 in Fk
Public funding (€554,753): Innovative Gene Therapy of Immunodeficiency (iGene) - Preclinical development of an in vivo secreted antiviral peptide (iSAVE) (subproject 2a) and preclinical testing of a …
9 Jan 2009
Patent: Secretable HIV Entry Inhibitory Peptides for Therapy of HIV Infection
21 Jul 2008
Patent: Gene Therapy of Chronic Granulomatous Disease
1 Jun 2008 in Fk
Public funding (€686,859): Leukemia: Molecular inhibitors of AML1/ETO oncogene function
1 Feb 2008 in Fk
Public funding (€797,735): RETARGET-IT: Generation and functional characterization of chimarcherersB2/HER2-specific antigen receptors (subproject 1) and generation and molecular characterization of …
9 Jan 2008
Patent: Secretable HIV Entry Inhibitory Peptides for Therapy of HIV Infection
Year 2007 in Epobase
4 European patent filings: Scaffold Proteins for Recombinant Peptide Aptamers …
1 Sept 2007 in Fk
Public funding (€240,692): Corus: Biomarkers for HIV diagnostics, subproject 1: Selection of peptide ligands by 'phage display technology'
29 Jun 2006
Patent: Expression Vector(s) for Enhanced Expression of a Protein of Interest in Eukaryotic or Prokaryotic Host Cells
1 Oct 2005 in Fk
Public funding (€675,493): 'TreatID': Subproject 6a (by Laer) Accompanying studies on gene therapy of AIDS-associated lymphoma and subproject 6b (Grez) follow-up studies for gene therapy of chronic …
14 Jul 2005
Patent: Gene Therapy of Solid Tumours by Means of Retroviral Vectors Pseudotyped with Arenavirus Glycoproteins
18 May 2005 as Georg-Speyer-Haus Chemotherapeutisches Forschungsinstitut
Patent: Valproic Acid and Derivatives Thereof AS Histone Deacetylase Inhibitors
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Creative Commons License The visualizations for "Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, Frankfurt a. Main, Germany" are provided by North Data and may be reused under the terms of the Creative Commons CC-BY license.

Printing is only available to North Data premium service subscribers.